pH-Triggered delivery of pirarubicin-gemcitabine duo using polymeric nanoparticles for synergistic breast cancer therapy.
Gupta P, Kaur H, Anees M, Tiwari S, Bansal A, Singh H.
Nanoscale Horiz · journal article · DOI 10.1039/d4nh00654b PUBLIKATIONSREGISTRET
Gå till forskningen.
Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.
Publikationer som ChEBI hänvisar till för pirarubicin. Visa hela publikationsregistret
En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.
Publikationer i urvalet
27 träffarUPLC-Q-TOF-MS based investigation into the bioactive compounds and molecular mechanisms of Qishen Huanwu capsule attenuates anthracycline-induced cardiotoxicity.
Lv JM, Wang LX, Yang J, Dong JJ, Feng NN, Liu HG, Zhao N, Yin GL, Wang F.
Phytomedicine · journal article · DOI 10.1016/j.phymed.2025.156877Comparison of hyperthermic intravesical chemotherapy using pirarubicin and Bacillus Calmette-Guérin in the treatment of patients with high-risk non-muscle-invasive bladder carcinoma: a retrospective study.
Huang Z, Huang S, Wu E, He Q, Wei X, Liang W.
BMC Urol · comparative study; research-article; journal article · DOI 10.1186/s12894-025-01773-zThe long-term impact of single intraoperative instillation of pirarubicin after radical nephroureterectomy on local and systemic cancer control: a prospective, multicenter, randomized trial.
Suzuki T, Kanematsu A, Tanaka S, Kanamaru S, Yamasaki T, Kawakita M, Yamamoto S.
World J Urol · multicenter study; randomized controlled trial; journal article · DOI 10.1007/s00345-025-05557-wAnalysis of the chemotherapy effect of albumin-bound paclitaxel combined with pirarubicin and cyclophosphamide on breast cancer and the effects of PCR, ORR, and CBR.
Liu Y, Gong K, Yuan S, Xu Y.
Pak J Med Sci · research-article; journal article · DOI 10.12669/pjms.41.3.9861circSTIL mediates pirarubicin inhibiting the malignant phenotype of triple-negative breast cancer and acts as a biomarker in plasma exosomes.
Ji J, Li M, Yan K, Ma J, Wei D, Zhang F, Qiao S, Huang P, Zhang W, Li L, Zheng W, Ren L.
Mol Immunol · journal article · DOI 10.1016/j.molimm.2025.02.014Efficacy of anlotinib and chemotherapy combination as neoadjuvant therapy in the treatment of pulmonary artery intimal sarcoma: a case report.
Liang G, Zhang Q, Luo Y, Zhao Y, Luo B.
Front Oncol · journal article; case reports; case-report · DOI 10.3389/fonc.2025.1507281CircDUSP16 mediates the effect of triple-negative breast cancer in pirarubicin via the miR-1224-3p/TFDP2 axis.
Wei D, Zhang F, Li M, Fan Z, Ma J, Ji J, Qiao S, Huang P, Zhang W, Fan K, Li L, Zheng W, Li X, Ren L.
Biochem Pharmacol · journal article · DOI 10.1016/j.bcp.2024.116719Transurethral resection of bladder tumor with Bacille Calmette-Guerin intravesical instillation for HRNMIBC and factors influencing recurrence.
Xu A, Liu M, Han C, Wang Z, Jia B, Zhao S.
Am J Transl Res · research-article; journal article · DOI 10.62347/uvff9164Folic acid-targeted redox responsive polylactic acid-based nanoparticles co-delivering pirarubicin and salinomycin suppress breast cancer tumor growth <i>in vivo</i>.
Gupta P, Bansal A, Kaur H, Anees M, Singh N, Singh H.
Nanoscale · journal article · DOI 10.1039/d4nr02365jAdenylate cyclase 1 knockdown attenuates pirarubicin-induced cardiotoxicity.
Zhang W, Shu Z, Huang P, Cheng H, Ji J, Wei D, Ren L.
Clin Exp Pharmacol Physiol · research support, non-u.s. gov't; journal article · DOI 10.1111/1440-1681.13920Comparison of neoadjuvant chemotherapy response and prognosis among pegylated liposomal doxorubicin, epirubicin and pirarubicin in HR ⩽ 10%/HER2-negative breast cancer: an exploratory real-world multicentre cohort study.
Hong Y, Peng J, Chen Q, Zhou Q, Xu F, Yao J, Zou Q, Yuan L, Li L, Long Q, Liao L, Liu M, Liu X, Zhang D, Wang S, Yi W.
Ther Adv Med Oncol · research-article; journal article · DOI 10.1177/17588359241279695Concomitant Delivery of Pirarubicin and Salinomycin Synergistically Enhanced the Efficacy of Cancer Therapy and Reduced the Risk of Cancer Relapse.
Anees M, Gupta P, Kaur H, Kharbanda S, Singh H.
AAPS PharmSciTech · journal article · DOI 10.1208/s12249-024-02918-3Pirarubicin combined with TLR3 or TLR4 agonists enhances anti-tumor efficiency.
Zhang R, Cui NP, He Y, Wang T, Feng D, Wang Y, Bao T, Su C, Qin Y, Shi JH, Li JH.
Int Immunopharmacol · journal article · DOI 10.1016/j.intimp.2024.113068Berberine increases the killing effect of pirarubicin on HCC cells by inhibiting ATG4B-autophagy pathway.
He H, He M, Wang Y, Xiong H, Xiong Y, Shan M, Liu D, Guo Z, Kou Y, Zhang Y, Yang M, Lian J, Sun L, He F.
Exp Cell Res · journal article · DOI 10.1016/j.yexcr.2024.114094Erratum: CircZCCHC2 decreases pirarubicin sensitivity and promotes triple-negative breast cancer development via the miR-1200/TPR axis.
Zhang F, Wei D, Xie S, Ren L, Qiao S, Li L, Ji J, Fan Z.
iScience · published erratum; correction · DOI 10.1016/j.isci.2024.109786Nucleus-targeting DNase I self-assembly delivery system guided by pirarubicin for programmed multi-drugs release and combined anticancer therapy.
He X, Liang D, Zhou J, Li K, Xie B, Liang C, Liu C, Chen Z, Chen X, Long A, Zhuo S, Su X, Luo Y, Chen W, Zhao F, Jiang X.
Int J Biol Macromol · journal article · DOI 10.1016/j.ijbiomac.2024.131514Food therapy of scutellarein ameliorates pirarubicin‑induced cardiotoxicity in rats by inhibiting apoptosis and ferroptosis through regulation of NOX2‑induced oxidative stress.
Lan Y, Tian F, Tang H, Pu P, He Q, Duan L.
Mol Med Rep · research-article; journal article · DOI 10.3892/mmr.2024.13208Isoquercitrin alleviates pirarubicin-induced cardiotoxicity <i>in vivo</i> and <i>in vitro</i> by inhibiting apoptosis through Phlpp1/AKT/Bcl-2 signaling pathway.
Wang L, Ma J, Chen C, Lin B, Xie S, Yang W, Qian J, Zhang Y.
Front Pharmacol · research-article; journal article · DOI 10.3389/fphar.2024.1315001An in situ forming gel co-loaded with pirarubicin and celecoxib inhibits postoperative recurrence and metastasis of breast cancer.
Wu M, Zhang W, Zhou X, Wang Z, Li S, Guo C, Yang Y, Zhang R, Zhang Z, Sun X, Gong T.
Int J Pharm · journal article · DOI 10.1016/j.ijpharm.2024.123897CircZCCHC2 decreases pirarubicin sensitivity and promotes triple-negative breast cancer development via the miR-1200/TPR axis.
Zhang F, Wei D, Xie S, Ren L, Qiao S, Li L, Ji J, Fan Z.
iScience · research-article; journal article · DOI 10.1016/j.isci.2024.109057Preparation and in Vitro Characterization of Fatty-Acid Modified Pirarubicin Nanosuspensions Stabilized by Albumin.
Hasegawa T, Tsukigawa K, Commey K, Sakuragi M, Imoto S, Taguchi K, Nishi K, Otagiri M, Yamasaki K.
Chem Pharm Bull (Tokyo) · journal article · DOI 10.1248/cpb.c23-00701Retracted: Inhibition of miR-15a-5p Promotes the Chemoresistance to Pirarubicin in Hepatocellular Carcinoma via Targeting eIF4E.
Methods In Medicine CAM.
Comput Math Methods Med · retraction of publication; retraction notice · DOI 10.1155/2023/9867851LncRNA Miat knockdown enhances pirarubicin-mediated anticancer sensitivity in breast cancer cells.
Huang P, Cheng H, Ji J, Zhang W, Ma J, Wei D, Ren L.
Environ Toxicol · journal article · DOI 10.1002/tox.23940The application of gemcitabine and pirarubicin in patients with non-muscle invasive bladder cancer.
Wang L, Huang S, Zhang P, Li H, Li Z, Xue L, Wang Z, Chen Q, Fu D, Luo Q, Li H.
J Cancer Res Clin Oncol · research-article; journal article · DOI 10.1007/s00432-023-04739-6Genome-Wide Screening Identifies Gene AKR1C1 Critical for Resistance to Pirarubicin in Bladder Cancer.
Nie Z, Gao Y, Chen M, Peng Y, Guo N, Cao H, Huang D, Gao X, Zhang S.
Cancers (Basel) · research-article; journal article · DOI 10.3390/cancers15092487[Pirarubicin (THP-adriamycin)].
Tsukagoshi S.
Gan To Kagaku Ryoho · review; journal article; english abstract